188 related articles for article (PubMed ID: 14977348)
1. Similar susceptibility to halothane, caffeine and ryanodine in vitro reflects pharmacogenetic variability of malignant hyperthermia.
Ginz HF; Girard T; Censier K; Urwyler A
Eur J Anaesthesiol; 2004 Feb; 21(2):151-7. PubMed ID: 14977348
[TBL] [Abstract][Full Text] [Related]
2. Results of contracture tests with halothane, caffeine, and ryanodine depend on different malignant hyperthermia-associated ryanodine receptor gene mutations.
Fiege M; Wappler F; Weisshorn R; Ulrich Gerbershagen M; Steinfath M; Schulte Am Esch J
Anesthesiology; 2002 Aug; 97(2):345-50. PubMed ID: 12151923
[TBL] [Abstract][Full Text] [Related]
3. Malignant hyperthermia (MH) diagnostics: a comparison between the halothane-caffeine- and the ryanodine-contracture-test results in MH susceptible, normal and control muscle.
Hartung E; Koob M; Anetseder M; Schoemig P; Krauspe R; Hogrefe G; Engelhardt W
Acta Anaesthesiol Scand; 1996 Apr; 40(4):437-44. PubMed ID: 8738688
[TBL] [Abstract][Full Text] [Related]
4. Comparative analysis of in vitro contracture tests with ryanodine and a combination of ryanodine with either halothane or caffeine: a comparative investigation in malignant hyperthermia.
Bendahan D; Guis S; Monnier N; Kozak-Ribbens G; Lunardi J; Ghattas B; Mattei JP; Cozzone PJ
Acta Anaesthesiol Scand; 2004 Sep; 48(8):1019-27. PubMed ID: 15315621
[TBL] [Abstract][Full Text] [Related]
5. Caffeine- or halothane-induced contractures of masseter muscle are similar to those of vastus muscle in normal humans.
Melton AT; Antognini JF; Gronert GA
Acta Anaesthesiol Scand; 1999 Aug; 43(7):764-9. PubMed ID: 10456818
[TBL] [Abstract][Full Text] [Related]
6. The ryanodine contracture test may help diagnose susceptibility to malignant hyperthermia.
Reuter DA; Anetseder M; Müller R; Roewer N; Hartung EJ
Can J Anaesth; 2003; 50(7):643-8. PubMed ID: 12944436
[TBL] [Abstract][Full Text] [Related]
7. Effects of caffeine, halothane, and 4-chloro-m-cresol on skeletal muscle lactate and pyruvate in malignant hyperthermia-susceptible and normal swine as assessed by microdialysis.
Bina S; Cowan G; Karaian J; Muldoon S; Mongan P; Bünger R
Anesthesiology; 2006 Jan; 104(1):90-100. PubMed ID: 16394695
[TBL] [Abstract][Full Text] [Related]
8. C1840-T mutation in the human skeletal muscle ryanodine receptor gene: frequency in northern German families susceptible to malignant hyperthermia and the relationship to in vitro contracture response.
Steinfath M; Singh S; Scholz J; Becker K; Lenzen C; Wappler F; Köchling A; Roewer N; Schulte am Esch J
J Mol Med (Berl); 1995 Jan; 73(1):35-40. PubMed ID: 7633940
[TBL] [Abstract][Full Text] [Related]
9. The differential effect of halothane and 1,2-dichlorohexafluorocyclobutane on in vitro muscle contractures of patients susceptible to malignant hyperthermia.
Kindler CH; Girard T; Gong D; Urwyler A
Anesth Analg; 2002 Apr; 94(4):1028-33, table of contents. PubMed ID: 11916818
[TBL] [Abstract][Full Text] [Related]
10. ATX II, a sodium channel toxin, sensitizes skeletal muscle to halothane, caffeine, and ryanodine.
Fletcher JE; Adnet PJ; Reyford H; Wieland SJ; Stewart SL; Rosenberg H
Anesthesiology; 1999 May; 90(5):1294-301. PubMed ID: 10319776
[TBL] [Abstract][Full Text] [Related]
11. RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes.
Robinson RL; Brooks C; Brown SL; Ellis FR; Halsall PJ; Quinnell RJ; Shaw MA; Hopkins PM
Hum Mutat; 2002 Aug; 20(2):88-97. PubMed ID: 12124989
[TBL] [Abstract][Full Text] [Related]
12. Treatment of normal skeletal muscle with FK506 or rapamycin results in halothane-induced muscle contracture.
Brooksbank RL; Badenhorst ME; Isaacs H; Savage N
Anesthesiology; 1998 Sep; 89(3):693-8. PubMed ID: 9743407
[TBL] [Abstract][Full Text] [Related]
13. Inositol 1,4,5-trisphosphate synthesis in mononuclear white blood cells of malignant hyperthermia-susceptible and normal human beings, following in vitro exposure to halothane, caffeine and ryanodine.
Martens U; Krause T; Scholz J; Wappler F; Steinrücke K; am Esch JS
Eur J Anaesthesiol; 2000 Jun; 17(6):364-72. PubMed ID: 10928436
[TBL] [Abstract][Full Text] [Related]
14. Comparison of in vitro contracture testing with ryanodine, halothane and caffeine in malignant hyperthermia and other neuromuscular disorders.
Hopkins PM; Ellis FR; Halsall PJ
Br J Anaesth; 1993 Apr; 70(4):397-401. PubMed ID: 8499197
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the segregation of the RYR1 C1840T mutation with segregation of the caffeine/halothane contracture test results for malignant hyperthermia susceptibility in a large Manitoba Mennonite family.
Serfas KD; Bose D; Patel L; Wrogemann K; Phillips MS; MacLennan DH; Greenberg CR
Anesthesiology; 1996 Feb; 84(2):322-9. PubMed ID: 8602662
[TBL] [Abstract][Full Text] [Related]
16. Ultrasound Elastography for Rapid, Real-time Detection of Localized Muscular Reaction in Malignant Hyperthermia-susceptible Pigs.
Johannsen S; Türkmeneli I; Isbary S; Roewer N; Schuster F
Anesthesiology; 2018 Nov; 129(5):989-999. PubMed ID: 30204593
[TBL] [Abstract][Full Text] [Related]
17. Reproducibility of in vitro contracture test results in patients tested for malignant hyperthermia susceptibility.
Islander G; Ording H; Bendixen D; Ranklev Twetman E
Acta Anaesthesiol Scand; 2002 Oct; 46(9):1144-9. PubMed ID: 12366511
[TBL] [Abstract][Full Text] [Related]
18. Effect of temperature variation (22 degrees C-44 degrees C) on halothane and caffeine contracture testing in normal humans.
Antognini JF; Gronert GA
Acta Anaesthesiol Scand; 1997 May; 41(5):639-42. PubMed ID: 9181168
[TBL] [Abstract][Full Text] [Related]
19. [Effect of chlorocresol vs caffeine on muscle contracture in malignant hyperthermia susceptible patients].
Ben-Abraham R; Krivosic-Horber RM; Haudcoeur G; Perel A; Adnet PJ
Harefuah; 1997 Jun; 132(12):839-41, 911. PubMed ID: 9264187
[TBL] [Abstract][Full Text] [Related]
20. Multicentre evaluation of in vitro contracture testing with bolus administration of 4-chloro-m-cresol for diagnosis of malignant hyperthermia susceptibility.
Wappler F; Anetseder M; Baur CP; Censier K; Doetsch S; Felleiter P; Fiege M; Fricker R; Halsall PJ; Hartung E; Heffron JJ; Heytens L; Hopkins PM; Klingler W; Lehmann-Horn F; Nivoche Y; Tegazzin V; Tzanova I; Urwyler A; Weisshorn R; Schulte am Esch J
Eur J Anaesthesiol; 2003 Jul; 20(7):528-36. PubMed ID: 12884985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
